Home › Companies › XENON PHARMACEUTICALS INC. › 2023-2024

XENON PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and XENON PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

  • 12Reported items
  • 225Asset managers
  • 2,526Fund votes
  • June 4, 2024Meeting date

Results at a glance

Meeting of June 4, 2024: 12 items on XENON PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2024: 8 elected · 4 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore XENON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by XENON PHARMACEUTICALS INC.

These tallies are XENON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

XENON PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 4, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dawn Svoronos 61,455,3584,487,857-- --2,559,642 93%Elected—
Elect Director: Gillian Cannon 65,895,89147,324-- --2,559,642 99.9%Elected—
Elect Director: Steven Gannon 65,709,645233,570-- --2,559,642 99.6%Elected—
Elect Director: Elizabeth Garofalo 62,307,3763,635,839-- --2,559,642 94%Elected—
Elect Director: Justin Gover 65,932,08311,132-- --2,559,642 99.9%Elected—
Elect Director: Patrick Machado 63,197,8192,745,396-- --2,559,642 96%Elected—
Elect Director: Ian Mortimer 65,768,424174,791-- --2,559,642 99.7%Elected—
Elect Director: Gary Patou 64,901,6601,041,555-- --2,559,642 98%Elected—
2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay") 63,950,0641,979,40213,742 --2,559,642 97%Approved—
3. Amendments to Amended and Restated 2014 Equity Plan 63,107,1282,823,05613,030 --2,559,643 96%Approved—
4. Appointment of Auditor 66,736,364---- 1,766,4930 97%Approved—
5. Remuneration of Auditor 65,671,700390,40613,121 --2,427,630 99.4%Approved—

Source: XENON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 5, 2024 — read the filing on EDGAR.

How asset managers voted at the XENON PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 225 asset managers that disclosed a XENON PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of XENON PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Dawn Svoronos

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 61,455,358AGAINST: 4,487,857
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Dawn Svoronos

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dawn Svoronos”): 61,455,358 for, 4,487,857 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Dawn Svoronos” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street9,334105,559 00Mixed
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,688,871 for, 142,232 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Dawn Svoronos” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

2. Elect Director: Elizabeth Garofalo

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 62,307,376AGAINST: 3,635,839
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Elizabeth Garofalo

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 62,307,376 for, 3,635,839 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Elizabeth Garofalo” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,794,430 for, 36,673 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Elizabeth Garofalo” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

3. Elect Director: Gary Patou

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 64,901,660AGAINST: 1,041,555
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Gary Patou

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gary Patou”): 64,901,660 for, 1,041,555 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Gary Patou” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,748,694 for, 82,409 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Gary Patou” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

4. Elect Director: Gillian Cannon

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 65,895,891AGAINST: 47,324
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Gillian Cannon

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gillian Cannon”): 65,895,891 for, 47,324 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Gillian Cannon” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,821,462 for, 9,641 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Gillian Cannon” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

5. Elect Director: Ian Mortimer

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 65,768,424AGAINST: 174,791
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Ian Mortimer

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Mortimer”): 65,768,424 for, 174,791 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Ian Mortimer” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,821,462 for, 9,641 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Ian Mortimer” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

6. Elect Director: Justin Gover

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 65,932,083AGAINST: 11,132
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Justin Gover

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Justin Gover”): 65,932,083 for, 11,132 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Justin Gover” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,821,462 for, 9,641 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Justin Gover” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

7. Elect Director: Patrick Machado

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 63,197,819AGAINST: 2,745,396
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Pat Machado

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Machado”): 63,197,819 for, 2,745,396 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Pat Machado” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco0536,645 00Against
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse80,621272,377 00Mixed
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional0330,624 00Against
Jackson National62,295231,866 00Mixed
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street9,334105,559 00Mixed
Principal109,8520 00For

Fund voting reports, all 67 managers: 23,317,034 for, 1,514,069 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Pat Machado” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

8. Elect Director: Steven Gannon

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 65,709,645AGAINST: 233,570
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Steven Gannon

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven Gannon”): 65,709,645 for, 233,570 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Election of Directors: Steven Gannon” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,821,462 for, 9,641 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Election of Directors: Steven Gannon” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

9. 3. Amendments to Amended and Restated 2014 Equity Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 63,107,128AGAINST: 2,823,056
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Equity Incentive Plan, including to increase the maximum number of Common Shares available for issuance thereunder by 5,200,000

XENON PHARMACEUTICALS INC.’s own tally for this item (“3. Amendments to Amended and Restated 2014 Equity Plan”): 63,107,128 for, 2,823,056 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposed amendments to the Company's Amended and Restated 2014 Equity Plan, including to increase the maximum number of common shares available for issuance thereunder by 5,200,000, were approved as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Eq” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM94,797326,932 00Mixed
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 9,6410For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam0238,670 00Against
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street9,334105,559 00Mixed
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,123,234 for, 698,228 against, 9,641 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 4 asset managers voting on “Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Eq” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
First Light Asset Management, LLC1,278,1550 00For
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For
ALGERT GLOBAL LLC27,7200 00For

Institutional-manager reports, all 4 managers: 2,303,553 for.

10. 2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay")

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 13 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 63,950,064AGAINST: 1,979,402
Details: description as filed, official tally, votes by 225 asset managers

Description as filed by funds: Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's named executive officers

XENON PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay")”): 63,950,064 for, 1,979,402 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, on an advisory basis, was approved as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's ” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 9,6410For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,756,659 for, 64,803 against, 9,641 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 175 asset managers voting on “Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's ” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,595,7770 00For
Capital Group5,157,3960 00For
Avoro Capital Advisors LLC4,192,5500 00For
Wellington3,648,6150 00For
DRIEHAUS CAPITAL MANAGEMENT LLC3,217,2990 00For
Polar Capital Holdings Plc2,508,7830 00For
Paradigm Biocapital Advisors LP2,445,3860 00For
COMMODORE CAPITAL LP2,167,7930 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,749,5550 00For
T. Rowe Price1,403,2270 00For
AllianceBernstein1,321,3530 00For
BRAIDWELL LP1,308,6770 00For
First Light Asset Management, LLC1,278,1550 00For
Rock Springs Capital Management LP1,255,5770 00For
PICTET ASSET MANAGEMENT SA1,230,3280 00For
Janus Henderson937,0470 00For
LORD, ABBETT & CO. LLC792,9070 00For
Affinity Asset Advisors, LLC772,8160 00For
Federated Hermes734,9000 00For
Avidity Partners Management LP710,0000 00For
Loomis Sayles674,7090 00For
TimesSquare Capital Management, LLC649,6780 00For
Invesco635,9770 00For
Boxer Capital, LLC600,0000 00For
MARSHALL WACE, LLP594,7120 00For

Institutional-manager reports, all 175 managers: 56,309,070 for, 1,453,020 against, 793 abstained, 1,100 not voted. Showing the 25 largest; see all in the interactive database.

11. 5. Remuneration of Auditor

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 65,671,700AGAINST: 390,406
Details: description as filed, official tally, votes by 70 asset managers

Description as filed by funds: Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditor of the Corporation

XENON PHARMACEUTICALS INC.’s own tally for this item (“5. Remuneration of Auditor”): 65,671,700 for, 390,406 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the ” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 9,6410For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,821,462 for, 9,641 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the ” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For
Jasper Ridge Partners, L.P.7340 00For

Institutional-manager reports, all 3 managers: 998,412 for.

12. Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meeting of…

Combines 4 wordings of this item as funds reported it.

99.8% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation or until their successors are duly elected

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 67 asset managers voting on “Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meet” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 09,641For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For
State Street114,8930 00For
Principal109,8520 00For

Fund voting reports, all 67 managers: 24,789,426 for, 41,677 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meet” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC649,6780 00For
Altium Capital Management LP348,0000 00For

Institutional-manager reports, all 2 managers: 997,678 for.

Largest XENON PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 75,459,681 shares outstanding at the time of that meeting.

Fund voting reports: top XENON PHARMACEUTICALS INC. shareholders by shares voted on “Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 8.31%
2Capital Group 6.83%
3Vanguard 3.73%
4BlackRock 1.94%
5T. Rowe Price 1.09%
6Federated Hermes 0.97%
7Lord Abbett 0.82%
8DRIEHAUS MUTUAL FUNDS 0.77%
9Bridge Builder Trust 0.74%
10Invesco 0.71%
Institutional-manager reports: top XENON PHARMACEUTICALS INC. shareholders by shares voted on “Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 8.74%
2Capital Group 6.83%
3Avoro Capital Advisors LLC 5.56%
4Wellington 4.84%
5DRIEHAUS CAPITAL MANAGEMENT LLC 4.26%
6Polar Capital Holdings Plc 3.32%
7Paradigm Biocapital Advisors LP 3.24%
8COMMODORE CAPITAL LP 2.87%
9ADAGE CAPITAL PARTNERS GP, L.L.C. 2.32%
10T. Rowe Price 1.86%

Reported XENON PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

XENON PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 11.82% 13F
Avoro Capital Advisors LLC 7.51% DEF14A
FMR LLC 7.50% DEF14A
BlackRock 6.32% 13F
Driehaus Capital Management LLC 5.76% DEF14A
Entities affiliated with Wellington Management Group LLP 5.52% DEF14A
Wellington Management 5.20% 13F
Capital International 3.28% 13F
JPMorgan Chase 1.85% 13F
Citadel Advisors 1.73% 13F

Percentages above are of 75,459,681 shares outstanding, as reported by XENON PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from XENON PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At XENON PHARMACEUTICALS INC.'s shareholder meeting held June 4, 2024, in the 2023-2024 proxy season, 225 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,526 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the… — XENON PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: XENON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2024.

XENON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.